

# [Vizgen, Hamamatsu partner to streamline spatial biology workflows](#)

written by CAP TODAY  
September 15, 2025

August 2025—Vizgen and Hamamatsu Photonics have entered a strategic partnership that integrates Hamamatsu's MoxiePlex multiplex immunofluorescence imaging system with Vizgen's reagent and assay portfolio. The companies plan to combine their expertise through validated InSituPlex panels, coupled with MoxiePlex, as an integrated multiplexed proteomic biomarker offering capable of multisite deployments for translational and clinical research applications.



©2026 CAP TODAY, all rights reserved.

---

# [MRC Holland assay for Peutz-Jeghers gains EU IVDR certification](#)

written by CAP TODAY  
September 15, 2025

August 2025—MRC Holland announced that its Salsa MLPA Probemix P101 STK11 assay for the detection of Peutz-Jeghers syndrome received the CE mark for in vitro diagnostic use under IVDR regulation EU 2017/746. The probe mix detects copy number variations in the *STK11* gene and has been updated with two improved and two newly added denaturation control probes that facilitate the detection of denaturation issues with exceptional sensitivity, according to a company press statement.



©2026 CAP TODAY, all rights reserved.

---

## **Radox unveils Evidence RABTA**

written by CAP TODAY  
September 15, 2025

August 2025—Radox has launched the Evidence RABTA (random access biochip technology analyzer), capable of processing up to 60 samples per hour and delivering up to 2,640 test results per hour. The analyzer offers seamless random access capabilities, allows users to assign samples as priority, and uses single-use tips for aspiration and dispensing. The time to first result is 36 minutes, with up to 44 results per sample. Walkaway time is up to 2.5 hours.



©2026 CAP TODAY, all rights reserved.

---

## **IDT unveils infectious disease research solutions**

written by CAP TODAY  
September 15, 2025

August 2025—Integrated DNA Technologies has unveiled its PrimeTime influenza kit and PrimeTime research pathogen panels. The influenza kit is a qPCR solution designed to amplify common influenza strains and targets influenza A, influenza A (H5N1), influenza B, and RNase. It includes an internal control for sample quality assessment, a premixed primer and probe set, PrimeTime 4x Broad-Range Master Mix, and direct amplification enhancer.



©2026 CAP TODAY, all rights reserved.

---

## [CytoChip showcases CLIA-waived CitoCBC at ADLM](#)

written by CAP TODAY  
September 15, 2025

August 2025—CytoChip showcased its flagship product, CitoCBC, a cartridge-based CBC analyzer, at the Association for Diagnostics and Laboratory Medicine annual meeting, July 27-31, in Chicago. CitoCBC delivers rapid CBC results with a five-part white blood cell differential from a cartridge-based system and requires only monthly quality control.



©2026 CAP TODAY, all rights reserved.

---

## [Precision Epigenomics presents Episeek MCED test results at ASCO](#)

written by CAP TODAY  
September 15, 2025

August 2025—Precision Epigenomics presented validation data for its flagship multicancer early detection (MCED) test, Episeek, at the 2025 ASCO annual meeting in Chicago, May 30-June 3. The data demonstrated that the blood-based test is capable of identifying more than 60 cancer types with a 99.5 percent specificity rate and a turnaround time of two to three days. The test was validated on 281 cancer-positive plasma samples across all four stages and 201 samples from healthy people over 40 years old. It showed a 45 percent sensitivity for stage I/II cancers and a 74 percent sensitivity for stage IV cancers, with positive and negative predictive values of 64.9 percent and 99.5 percent, respectively.



## **CRCdx RAS mutation detection kit gets CMS coverage**

written by CAP TODAY  
September 15, 2025

August 2025—EntroGen announced that its CRCdx RAS mutation detection kit has received national coverage from the Centers for Medicare and Medicaid Services. CRCdx is an FDA-approved, real-time PCR-based companion diagnostic for use in identifying patients eligible for treatment with Vectibix (panitumumab), based on the absence of *KRAS* and *NRAS* mutations.



©2026 CAP TODAY, all rights reserved.

---

## **Qiagen launches QIAseq, QIAcuity products**

written by CAP TODAY  
September 15, 2025

August 2025—Qiagen announced a series of product and partnership updates, including a new set of QIAseq panels for comprehensive genomic profiling, a QIAcuity digital PCR kit and assays for cell and gene therapy quality control, and a free, limited version of the Human Somatic Mutation Database from the Qiagen Digital Insights bioinformatics business.



©2026 CAP TODAY, all rights reserved.

---

## **Revvity launches IDS i20 platform from Euroimmun**

written by CAP TODAY  
September 15, 2025

August 2025—Revvity announced the launch of its IDS i20 analytical random access platform from Euroimmun, enabling full automation of chemiluminescence immunoassays. The CE-marked and FDA-listed IDS i20 allows users to simultaneously run 20 analytes from six diagnostic specialties on a single device. The specialties include endocrinology, allergy, autoimmune and infectious disease testing, testing for Alzheimer’s disease, and therapeutic drug monitoring. The instrument can process up to 140 tests per hour and features continuous loading of samples and reagents as well as integrated cooling of ready-to-use reagent cartridges. It is for in vitro diagnostic use.



©2026 CAP TODAY, all rights reserved.

---

## **Voicebrook, Gestalt offer fully speech-enabled DP solution**

written by CAP TODAY  
September 15, 2025

Sept. 12, 2025—Voicebrook’s VoiceOver Pro reporting platform now connects with Gestalt’s PathFlow digital pathology platform, giving pathologists the ability to navigate images and create reports entirely by voice.



©2026 CAP TODAY, all rights reserved.